JP2013500324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500324A5 JP2013500324A5 JP2012522250A JP2012522250A JP2013500324A5 JP 2013500324 A5 JP2013500324 A5 JP 2013500324A5 JP 2012522250 A JP2012522250 A JP 2012522250A JP 2012522250 A JP2012522250 A JP 2012522250A JP 2013500324 A5 JP2013500324 A5 JP 2013500324A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fulvestrant
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 3
- 229960002258 fulvestrant Drugs 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 238000009261 endocrine therapy Methods 0.000 claims 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
| GB0912999.0 | 2009-07-27 | ||
| PCT/GB2010/051228 WO2011012885A1 (en) | 2009-07-27 | 2010-07-26 | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500324A JP2013500324A (ja) | 2013-01-07 |
| JP2013500324A5 true JP2013500324A5 (enExample) | 2013-06-27 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522250A Pending JP2013500324A (ja) | 2009-07-27 | 2010-07-26 | 進行乳癌の処置のための投与量５００ｍｇでのフルベストラント |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP2017515873A (ja) * | 2014-05-21 | 2017-06-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋ阻害剤ピクチリシブでのｐｒ陽性ルミナールａ乳がんの処置方法 |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| EP3528818B1 (en) * | 2016-10-21 | 2021-09-15 | Crescita Therapeutics Inc. | Pharmaceutical compositions |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 RS RS20120022A patent/RS20120022A1/sr unknown
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Withdrawn
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 FI FI20125207A patent/FI20125207L/fi not_active Application Discontinuation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en not_active Ceased
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039771A5 (enExample) | ||
| JP2018514593A5 (enExample) | ||
| JP2013500324A5 (enExample) | ||
| Kümler et al. | Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant | |
| JP2011518883A5 (enExample) | ||
| ECSP10010016A (es) | Composiciones de dhea para el tratamiento de la menopausia | |
| RU2017140674A (ru) | Способы лечения рака | |
| HRP20150294T1 (hr) | Parenteralni farmaceutski oblik koji otpušta inhibitor aromataze i gestagene, za lijeäśenje endometrioze | |
| RU2013118325A (ru) | Лечение рака молочной железы | |
| IN2012DN04867A (enExample) | ||
| HRP20210572T1 (hr) | Kombinacijsko liječenje raka | |
| JP2016528246A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2013542190A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2019529581A5 (enExample) | ||
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди | |
| JP2019526632A5 (enExample) | ||
| LT2012006A (lt) | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui | |
| JP2019501957A5 (enExample) | ||
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| RU2015139515A (ru) | Комбинированное лечение | |
| WO2018204138A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| JP2015506988A5 (enExample) |